Abstract RF3-04: Tumor-informed circulating tumor DNA analysis to assess molecular residual disease for prognosis and prediction of benefit from palbociclib in the PALLAS trial
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Authors: H. A. Parsons, K. Ballman, E. Heitzer, M. Watson, M. Balic, D. Hlauschek, D. Renner, E. Kalashnikova, G. Steger, J. M. Balko, Y. Novik, M. Martin, A. A. Rodriguez, Z. Dayao, A. Chan, E. Nili Gal-Yam, M. C. Liu, C. Isaacs, M. Los, M. Gil Gil, B. Felder, C. Denkert, P. Fasching, F. Liu, T. O'Donnell, E. L. Mayer, M. Gnant, W. F. Symmans, A. DeMichele
Institutions: Fred Hutch Cancer Center, Mayo Clinic, Medical University of Graz, Washington University in St. Louis, University of Pittsburgh, UPMC Hillman Cancer Center, Austrian Breast & Colorectal Cancer Study Group, Natera (United States), Medical University of Vienna, Vanderbilt University Medical Center, NYU Langone Health, New York University, Hospital General Universitario Gregorio Marañón, University of New Mexico, Sheba Medical Center, Georgetown University, St. Antonius Ziekenhuis, Institut Català d'Oncologia, Philipps University of Marburg, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen, Pfizer (United States), Alliance Foundation Trials, Dana-Farber Cancer Institute, Comprehensive Cancer Center Vienna, The University of Texas MD Anderson Cancer Center, University of Pennsylvania
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129706045